Research programme: factor Xa inhibitors - Celera Genomics
Alternative Names: Factor Xa inhibitors research programme - Celera GenomicsLatest Information Update: 24 Sep 2021
At a glance
- Originator Celera Genomics Group; Pfizer
- Class
- Mechanism of Action Factor Xa inhibitors; Serine endopeptidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Blood coagulation disorders
Most Recent Events
- 04 Feb 2004 Discontinued - Preclinical for Coagulation disorders in USA (PO)
- 16 Apr 2003 Pharmacia Corporation has been acquired by, and merged into, Pfizer
- 04 Dec 2001 Axys Pharmaceuticals has been acquired by Celera Genomics Group